MedTech Funding Mandate
In collaboration with Accelerated Access Collaborative (AAC) and The AHSN Network.
The NHS Long Term Plan committed to accelerate the uptake of selected innovative medical devices, diagnostics and digital products to patients faster, by developing the MedTech Funding Mandate policy, which is delivered in partnership with AHSNs.
The MedTech Funding Mandate policy launch was delayed due to the COVID-19 pandemic. It was launched on the 1 April 2021. The guidance for 2022/23 is published here.
In 2021/22 the policy will support devices, diagnostics or digital products that:
- are effective: demonstrated through positive NICE guidance;
- deliver material savings to the NHS: the benefits of the innovation are over £1 million over five years for the population of England;
- are cost-saving in-year: NICE modelling demonstrates a net saving in the first 12 months of implementing the technology;
- are affordable to the NHS: the budget impact should not exceed £20 million, in any of the first three years.
To minimise burden on the NHS at this time, it was agreed that for the first year of the policy only, technologies must have also been previously supported by the Innovation Technology Payment.
The technologies that will be supported by the policy during 2022/2023 are:
Technology: BPH Group
Products for improving the patient experience during procedures
For more information on the products for improving the patient experience during procedures, please contact: Cath Barrow, Senior Programme Development Lead, Delivery and Development Team at Health Innovation Manchester, or Maryam Aziz, Programme Development Lead, Delivery & Development Team at Health Innovation Manchester.